[사진=게티이미지뱅크]
Alteogen’s stock price is rising.
According to the Korea Exchange on the 2nd, as of 9:55 am, Alteogen is trading at 79,100 won, up 6.89% (5,100 won) from the previous day.
Alteogen’s market capitalization is 3.33 trillion won, ranking 11th on the KOSDAQ. The par price is 500 won per share.
On this day, Alteogen announced that the development project for the treatment of acromegaly (ALT-B5), which has increased durability in the body, was selected as the ‘2021 1st national drug development project’ by the National New Drug Development Foundation.
‘Alt-B5’ is an orphan drug, a next-generation treatment that can last for a long time in the body and produce efficacy with a small dose by using a self-developed long-acting platform technology.
An official from the company said, “The acromegaly treatment (ALT-B5) applied to the company’s long-acting source technology is being developed as a liquid formulation that improves the convenience of existing treatments and reduces the number of administrations by increasing the efficacy. Selected as a national new drug development project Accordingly, clinical research on acromegaly treatment using long-acting original technology will be accelerated,” he said.
© ‘Global Economic Daily in 5 Languages’ Aju Economic Daily. Unauthorized reproduction and redistribution prohibited
.
